Strategic partnerships Leverage the AllStripes platform’s patient-centered data approach to offer end-to-end evidence-generation programs for rare-disease drug development. Emphasize services that deliver regulatory-grade, consented clinical data for trials, endpoints, and regulatory submissions. This provides pharma and biotech teams a faster path to reliable real-world evidence.

Existing relationships Target former AllStripes pharma relationships such as Novartis, Ultragenyx, and UCB with renewal and expansion opportunities. Propose deeper data integrations, larger patient cohorts, and ongoing real-world evidence feeds to support ongoing development pipelines and post-approval commitments.

Data compliance Highlight HIPAA-aligned data capture and robust consent management as differentiators for trials requiring strict governance. Show how structured datasets can accelerate recruitment, eligibility screening, and evidence generation while meeting regulatory expectations.

Collaborative funding Leverage a history of NCATS collaboration to access government-funded translational research programs. Seek co-funding pilots or grant-supported studies with agencies and academic centers focused on rare diseases and translational science.

Post‑acquisition synergy Explore cross-sell opportunities as AllStripes integrates with PicnicHealth, offering a broader data-network and services. Propose bundled solutions combining patient consent, medical-record acquisition, and real-world evidence generation for pharma, CROs, and healthcare researchers.